American Standard throws in towel and sells back DiaSorin
This article was originally published in Clinica
After a brief foray into the medical diagnostics business, American Standard has admitted defeat and has sold its DiaSorin business. It goes to a management buyout backed by an investment banks and the Italian SNIA conglomerate - the same company that sold the diagnostics business to American for $220 million in cash, three years ago (see Clinica No 742, p 1).
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.